Free Trial

McKesson (MCK) Stock Forecast & Price Target

McKesson logo
$579.13 +2.37 (+0.41%)
(As of 01:10 PM ET)

McKesson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
14

Based on 16 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for MCK.

Consensus Price Target

$650.14
12.26% Upside
According to the 16 analysts' twelve-month price targets for McKesson, the average price target is $650.14. The highest price target for MCK is $713.00, while the lowest price target for MCK is $579.00. The average price target represents a forecasted upside of 12.26% from the current price of $579.13.
Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

Sign Up

MCK Analyst Ratings Over Time

TypeCurrent Forecast
12/25/23 to 12/24/24
1 Month Ago
11/25/23 to 11/24/24
3 Months Ago
9/26/23 to 9/25/24
1 Year Ago
12/25/22 to 12/25/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
8 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$650.14$631.57$613.36$480.31
Forecasted Upside12.26% Upside1.34% Upside27.99% Upside5.75% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

McKesson Stock vs. The Competition

TypeMcKessonMedical CompaniesS&P 500
Consensus Rating Score
2.94
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside12.72% Upside25,626.32% Upside14.28% Upside
News Sentiment Rating
Positive News

See Recent MCK News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/17/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$612.00 ➝ $642.00+14.35%
12/13/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$535.00 ➝ $641.00+10.71%
12/4/2024Mizuho
3 of 5 stars
S. Valiquette
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$630.00+1.95%
11/13/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$630.00 ➝ $713.00+13.73%
11/7/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/7/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$560.00 ➝ $680.00+23.79%
11/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$531.00 ➝ $688.00+25.25%
10/7/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$665.00 ➝ $630.00+29.78%
9/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$623.00 ➝ $579.00+20.99%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$656.00 ➝ $661.00+19.54%
8/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$596.00 ➝ $616.00+12.78%
6/25/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$590.00 ➝ $670.00+10.23%
6/24/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$570.00 ➝ $670.00+11.10%
5/8/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$563.00 ➝ $652.00+19.74%
5/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$620.00 ➝ $630.00+14.00%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$450.00 ➝ $485.00+11.71%
5/9/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:52 PM ET.


Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 18, 2024. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in McKesson Co.:

  • McKesson Co. has shown strong institutional support, with 85.07% of its stock owned by institutional investors, indicating confidence in the company's future performance.
  • The stock is currently trading at $576.40, which is near its 12-month high of $637.51, suggesting a robust market position and potential for further growth.
  • Recent insider trading activity shows that executives are actively managing their positions, with a notable sale by EVP Leann B. Smith, which can indicate a strategic approach to stock management.
  • McKesson Co. has a solid market capitalization of $73.17 billion, reflecting its significant size and stability in the healthcare sector.
  • The company has a relatively low beta of 0.49, suggesting that its stock is less volatile compared to the market, which can be appealing for risk-averse investors.

McKesson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in McKesson Co. for these reasons:

  • Despite the strong institutional ownership, the recent sale of shares by Barclays PLC, which reduced its stake by 18.5%, may raise concerns about the stock's short-term outlook.
  • The stock has experienced fluctuations, with a 12-month low of $431.35, indicating potential volatility that could deter some investors.
  • Insider ownership is relatively low at 0.11%, which may suggest a lack of alignment between management and shareholder interests.
  • The price-to-earnings (P/E) ratio of 29.73 is higher than the industry average, which could indicate that the stock is overvalued compared to its earnings potential.
  • Recent trading volumes have varied, with only 1,093,719 shares traded on a day when the average volume was 818,423, suggesting potential liquidity concerns.

MCK Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $650.14, with a high forecast of $713.00 and a low forecast of $579.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 12.26% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 2 upgrades by analysts.

McKesson has been rated by research analysts at Baird R W, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore ISI, Leerink Partners, Mizuho, Morgan Stanley, Robert W. Baird, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "medical" companies. The consensus rating score for McKesson is 2.94 while the average consensus rating score for "medical" companies is 2.81. Learn more on how MCK compares to other companies.


This page (NYSE:MCK) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners